PDL BIOPHARMA INC's ticker is PDLI and the CUSIP is 69329Y104. A total of 176 filers reported holding PDL BIOPHARMA INC in Q1 2018. The put-call ratio across all filers is 1.67 and the average weighting 0.0%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2020 | $694,000 | -2.8% | 220,751 | -10.0% | 0.00% | -100.0% |
Q2 2020 | $714,000 | +310.3% | 245,313 | +297.9% | 0.00% | – |
Q1 2020 | $174,000 | -47.3% | 61,659 | -39.4% | 0.00% | – |
Q4 2019 | $330,000 | +78.4% | 101,737 | +18.8% | 0.00% | – |
Q3 2019 | $185,000 | -44.4% | 85,646 | -19.4% | 0.00% | – |
Q2 2019 | $333,000 | -6.5% | 106,281 | +11.1% | 0.00% | – |
Q1 2019 | $356,000 | -14.0% | 95,672 | -33.1% | 0.00% | – |
Q4 2018 | $414,000 | +9.2% | 143,054 | -0.6% | 0.00% | – |
Q3 2018 | $379,000 | -36.8% | 143,951 | -43.8% | 0.00% | -100.0% |
Q2 2018 | $600,000 | -18.7% | 256,200 | +2.1% | 0.00% | 0.0% |
Q1 2018 | $738,000 | -14.6% | 250,858 | -20.4% | 0.00% | 0.0% |
Q4 2017 | $864,000 | -29.1% | 315,063 | -12.3% | 0.00% | 0.0% |
Q3 2017 | $1,218,000 | +135.1% | 359,394 | +71.6% | 0.00% | 0.0% |
Q2 2017 | $518,000 | -1.3% | 209,399 | -9.4% | 0.00% | – |
Q1 2017 | $525,000 | -8.4% | 231,001 | -14.6% | 0.00% | -100.0% |
Q4 2016 | $573,000 | -36.5% | 270,645 | +0.5% | 0.00% | 0.0% |
Q3 2016 | $902,000 | -13.8% | 269,295 | -19.3% | 0.00% | 0.0% |
Q2 2016 | $1,047,000 | +18.2% | 333,591 | +25.4% | 0.00% | 0.0% |
Q1 2016 | $886,000 | -0.3% | 266,030 | +5.8% | 0.00% | 0.0% |
Q4 2015 | $889,000 | +14.1% | 251,387 | +62.2% | 0.00% | 0.0% |
Q3 2015 | $779,000 | -68.0% | 155,026 | -59.0% | 0.00% | -50.0% |
Q2 2015 | $2,431,000 | +28.9% | 377,998 | +41.0% | 0.00% | 0.0% |
Q1 2015 | $1,886,000 | -9.2% | 268,000 | -0.5% | 0.00% | 0.0% |
Q4 2014 | $2,078,000 | -7.3% | 269,481 | -10.2% | 0.00% | 0.0% |
Q3 2014 | $2,242,000 | -23.3% | 300,195 | -0.6% | 0.00% | 0.0% |
Q2 2014 | $2,924,000 | +37.3% | 302,067 | +17.9% | 0.00% | 0.0% |
Q1 2014 | $2,130,000 | -56.0% | 256,255 | -55.3% | 0.00% | -50.0% |
Q4 2013 | $4,836,000 | +24.4% | 572,974 | +17.5% | 0.00% | 0.0% |
Q3 2013 | $3,887,000 | -10.4% | 487,749 | -13.2% | 0.00% | 0.0% |
Q2 2013 | $4,339,000 | -3.2% | 561,978 | -8.5% | 0.00% | -20.0% |
Q1 2013 | $4,482,000 | – | 613,998 | – | 0.01% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
ARMISTICE CAPITAL, LLC | 2,632,000 | $8,817,000 | 2.83% |
AMERICAFIRST CAPITAL MANAGEMENT, LLC | 551,804 | $1,848,543,000 | 1.54% |
Nine Chapters Capital Management LLC | 24,300 | $81,000 | 0.57% |
GREAT POINT PARTNERS LLC | 645,000 | $2,161,000 | 0.55% |
Virtus ETF Advisers LLC | 198,901 | $666,000 | 0.32% |
GSA CAPITAL PARTNERS LLP | 1,521,224 | $5,096,000 | 0.27% |
Amici Capital, LLC | 200,000 | $670,000 | 0.18% |
Acrospire Investment Management LLC | 70,622 | $237,000 | 0.16% |
RBF Capital, LLC | 273,976 | $918,000 | 0.16% |
SECOR Capital Advisors, LP | 383,971 | $1,286,000 | 0.14% |